Black Diamond Therapeutics develops cancer drugs that target families of related gene mutations in patients with tumors. It last closed at $1.44 on Nov 17, down 5.88% on the day.
Only 1 firm rated BDTX in the past 90 days, not enough for a consensus
Average 12-month target
$11.00
▲ 663.9% upside
Based on 1 analyst who set a price target on BDTX in the past 90 days. The average target is $11.00, with a high of $11.00 and a low of $11.00, compared with the last close of $1.44.
Low $11.00Avg $11.00High $11.00
Blue marker: last close $1.44
Highest target$11.00
Average target$11.00
Lowest target$11.00
Latest rating changes
HC Wainwright & Co.Reiterated
Oct 29Buy$11
StifelReinstated
Oct 16Buy$8
Raymond JamesReinstated
Jul 1Buy$11
Date
Firm
Action
Rating
Price target
Oct 29
HC Wainwright & Co.
Reiterated
Buy
$11
Oct 16
Stifel
Reinstated
Buy
$8
Jul 1
Raymond James
Reinstated
Buy
$11
Loading…
Technical Analysis
BDTX · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold
The stock is 21% below its 20 day and 27% below its 50 day average. It is 48% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 37), near oversold. The nearest support is the 52 week low at $1.39, and the nearest resistance the Pivot R1 at $1.50.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 9.9%/day
Key levels
$4.2052 week high+191.7%
$2.14200 day average+48.6%
$1.89100 day average+31.3%
$1.87Swing high (Oct 12)+29.9%
$1.8350 day average+27.1%
$1.7420 day average+20.8%
$1.50Pivot R1+4.2%
$1.44Pivot+0.0%
$1.44Last close
$1.3952 week low−3.5%
$1.39Pivot S1−3.5%
Indicators
RSI (14)
37.32
Weak, oversold below 30
Neutral
MACD
-0.10
Below its signal line
Bearish
Stochastic
11.9
Near the bottom of its range
Oversold
ADX (14)
18.5
No clear trend
Williams %R
-91.3
Oversold below −80, overbought above −20
Oversold
CCI (20)
-157.9
Oversold below −100, overbought above 100
Oversold
Rate of change
−20.4%
Change over 10 sessions
Bearish
ATR (14)
$0.14
Typical daily range, 9.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, nearing oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityLow, 20.7%/day
Key levels
$4.2052 week high+191.7%
$2.14200 day average+48.6%
$1.89100 day average+31.3%
$1.87Swing high (Oct 12)+29.9%
$1.8350 day average+27.1%
$1.7420 day average+20.8%
$1.50Pivot R1+4.2%
$1.44Pivot+0.0%
$1.44Last close
$1.3952 week low−3.5%
$1.39Pivot S1−3.5%
Indicators
RSI (14)
34.64
Weak, oversold below 30
Neutral
MACD
-0.17
Below its signal line
Bearish
Stochastic
8.8
Near the bottom of its range
Oversold
ADX (14)
11.5
No clear trend
Williams %R
-94.7
Oversold below −80, overbought above −20
Oversold
CCI (20)
-206.7
Oversold below −100, overbought above 100
Oversold
Rate of change
−27.3%
Change over 10 sessions
Bearish
ATR (14)
$0.30
Typical daily range, 20.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for BDTX
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how BDTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow BDTX usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How BDTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BDTX is in one of them and how their past BDTX trades turned out.
Black Diamond Therapeutics is a drug developer based in Cambridge, Massachusetts. It develops cancer medicines designed to block families of related gene mutations rather than a single mutation, aiming to treat patients whose tumors have limited treatment options. Its lead candidate, silevertinib, is being tested in patients with lung cancer and brain tumors. The company has also licensed another candidate to Servier, which is developing it for cancer and genetic diseases.